First-degree relatives of patients with multiple myeloma were found to be at a higher risk of developing monoclonal gammopathy of undetermined significance.
For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.
Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.
The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.
Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.
Transplant-naive patients were more likely to achieve an optimal drug response — but were also more prone to severe cytokine release syndrome and neurotoxicity.
Baseline ctDNA levels and, separately, measures of molecular response, were prognostic for outcome in patients with diffuse large B-cell lymphoma.
The manufacturing approach yielded therapeutic doses of engineered T cells with activity against NKG2D ligands in acute myeloid leukemia and multiple myeloma.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
Previous studies showed that elotuzumab plus lenalidomide and dexamethasone improved progression-free survival and response rates, but its impact on patient-reported outcomes is unknown.
Progressive telomere shortening during successive cell divisions is thought to contribute to phase transition in chronic myeloid leukemia.
Signal strength of the receptors used to create CAR-T therapies in lymphoma varied depending on the signaling domain chosen for each investigational construct.
Rituximab plus lenalidomide immunotherapy may be an effective alternative to chemotherapy for patients with follicular lymphoma.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Researchers hypothesized that a combination bispecific mAb in B-cell malignancies could offer a treatment option superior to existing monospecific mAbs.
Circulating tumor DNA levels measured as early as 3 weeks post-therapy may provide clues about long-term outcomes in this lymphoma subtype.
The feasibility of lenalidomide in combination therapy for chronic lymphocytic leukemia is in question.
Researchers investigated cancer-related fatigue in 16 patients with multiple myeloma who were treated with bortezomib, lenalidomide, or thalidomide.
Abdominal adiposity was determined to be a better predictor of risk for hematological malignancies compared with BMI.
Ibrutinib May Be Effective in Patients With Chronic Lymphocytic Leukemia Who Were Excluded from Clinical TrialsAugust 30, 2018
The RESONATE-2 trial excluded certain patients with chronic lymphocytic leukemia, leaving the efficacy and tolerability of ibrutinib in this population unknown.
There is paucity of comparative and efficacy information on novel agents used as frontline induction therapies in multiple myeloma.
Levels of hemoglobin, combined with ESR, PV, and calcium values, were determined to be the blood parameters with the most diagnostic value in multiple myeloma.
Rituximab plus ibrutinib is the first nonchemotherapy combination regimen approved in Waldenström macroglobulinemia.
Many patients with follicular lymphoma will be asymptomatic and present with variable cervical, axillary, and inguinal adenopathy.
New evidence appears to support the potential utility of checkpoint inhibitors in Waldenström macroglobulinemia.
Due to its rarity, there is neither robust evidence nor many completed studies supporting specific treatment regimens in Waldenström macroglobulinemia.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
Early preclinical and clinical data have shown that selinexor has broad activity against multiple hematologic malignancies and notable antimyeloma activity.
Albumin-to-fibrinogen ratio may predict poor outcomes in patients with previously untreated chronic lymphocytic leukemia.
No direct comparison between ibrutinib and chemoimmunotherapy as a first-line treatment exists.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML